Cobblestone Capital Advisors LLC NY Sells 147 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Cobblestone Capital Advisors LLC NY lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,343 shares of the medical equipment provider’s stock after selling 147 shares during the period. Cobblestone Capital Advisors LLC NY’s holdings in Zimmer Biomet were worth $361,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. American Century Companies Inc. increased its stake in Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Equity Investment Corp acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $70,104,000. Magnetar Financial LLC raised its stake in Zimmer Biomet by 58.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock worth $142,203,000 after acquiring an additional 484,816 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC acquired a new position in Zimmer Biomet in the 3rd quarter worth approximately $41,588,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE ZBH opened at $112.10 on Monday. The firm has a market cap of $22.32 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company’s 50-day simple moving average is $107.29 and its 200-day simple moving average is $109.30. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.65 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on ZBH shares. UBS Group dropped their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Evercore ISI cut their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. BTIG Research decreased their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. TD Cowen reduced their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Finally, Canaccord Genuity Group decreased their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 10th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.